VENGLUSTAT - Emerging Insight and Market Forecast - 2030
Biomolecules | Free Full-Text | The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers
Progress towards therapies for disease modification in Parkinson's disease - The Lancet Neurology
Sanofi halts venglustat clinical programme in kidney disease
Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study - ScienceDirect
Sanofi's venglustat fails another trial, ending pursuit of kidney disease | Fierce Biotech
Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease. - Abstract - Europe PMC
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
Novel targeted therapies for Parkinson's disease | Molecular Medicine | Full Text
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020 - IOS Press
Cells | Free Full-Text | Recent Advances in the Treatment of Genetic Forms of Parkinson’s Disease: Hype or Hope?
PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial - ScienceDirect
Ziv Gan-Or on Twitter: "Despite being completely unclear whether glucosylceramide is relevant is PD, the plans for the trial continued as usual. Now, let's talk about some pre-clinical results, using mouse "PD
Gaucher Treatment Report
%20for%20Fabry%20Disease.png?md=1 "Venglustat (GZ402671) for Fabry Disease Clinical Trial 2023 | Power")
Venglustat (GZ402671) for Fabry Disease Clinical Trial 2023 | Power
Venglustat Lowers Gb3 With No Signs of Disease Progression in Trial | Venglustat Led to Long-term Benefits in 5 of 6 Men in Phase 2 Trial | Fabry Disease News
venglustat | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports
Pharmacokinetics, Safety, and Tolerability of Single-Dose Orally Administered Venglustat in Healthy Chinese Volunteers | SpringerLink
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020 - IOS Press
Genes | Free Full-Text | The Genetics of Parkinson's Disease and Implications for Clinical Practice
